Nachrichten und Videos - IRHYTHM TECHNOLOGIES INC.

IRHYTHM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC PR Newswire NEW ORLEANS, Oct. 11, 2024 NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC). On May 30, 2023 ,...

Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trial Zio ECG monitoring system previously received Japanese high medical needs designation, a unique distinction reflecting positive recommendation by the Japanese Heart Rhythm Society (JHRS) iRhythm will continue working towards reimbursement to enable market access in Japan, the world’s second largest medical device...

iRhythm’s next-generation Zio ® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio ® XT device. Longer wear duration and analyzable time may further improve diagnostic yield, building upon Zio XT service’s superior yield among ambulatory cardiac monitoring services as demonstrated by the prior CAMELOT study findings. 1 The Zio monitor ECG device has been worn by over 1 million patients since launching in late 2023. 2 SAN FRANCISCO, Sept. 09,...

SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has signed an exclusive license agreement with BioIntelliSense, Inc ., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring (ACM). “As a...

GUARD-AF trial results presented at European Society of Cardiology (ESC) Congress 2024 Leveraging iRhythm’s Zio ® patch-based long-term continuous monitoring (LTCM), GUARD-AF is the largest randomized trial in a primary care setting to evaluate the impact of screening for undiagnosed atrial fibrillation (AF) Screening with iRhythm’s Zio ® XT 1 LTCM led to increase in new diagnosis of AF (5.0% vs 3.3%) over an average follow-up of 15 months. No difference in stroke hospitalization vs usual...

Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio ® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization Software) System (iRhythm’s advanced AI algorithm), and a comprehensive end-of-wear report reviewed and curated by certified cardiographic technicians. The next-generation Zio monitor LTCM provides up to 14 days of continuous, uninterrupted, patch-based ECG monitoring, marking a significant advancement in these...

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September: Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern Time Wells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern...

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm’s current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the...

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $148.0 million, a 19.3% increase compared to second quarter 2023 Gross margin of 69.9%, a 40-basis point increase compared to second quarter 2023 Unrestricted...

SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a...

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings. In...

SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, June 18, at 9:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of...

SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming William Blair 44 th Annual Growth Stock Conference. iRhythm’s management is scheduled to present on Wednesday, June 5, at 11:20 a.m. Central Time. Interested parties may access a live and archived webcast of the...

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023 Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023 Unrestricted cash,...

SAN FRANCISCO, April 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2024 after the close of trading on Thursday, May 2, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live...

Shareholders that lost money on iRhythm Technologies, Inc.(IRTC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire NEW YORK, April 8, 2024 NEW YORK , April 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in iRhythm Technologies, Inc. ("iRhythm Technologies" or the "Company") (NASDAQ: IRTC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of iRhythm Technologies investors who were adversely...

IRTC DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important April 8 Deadline in Securities Class Action - IRTC PR Newswire NEW YORK, April 6, 2024 NEW YORK , April 6, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of iRhythm Technologies, Inc. (NASDAQ: IRTC) between January 11, 2022 and May 30, 2023 , both dates inclusive (the "Class Period"), of the important...

Investors who lost money on iRhythm Technologies, Inc.(IRTC) should contact The Gross Law Firm about pending Class Action - IRTC PR Newswire NEW YORK, April 5, 2024 NEW YORK , April 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of iRhythm Technologies, Inc. (NASDAQ: IRTC). Shareholders who purchased shares of IRTC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff...

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against iRhythm Technologies, Inc. - IRTC PR Newswire NEW YORK, April 4, 2024 NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against iRhythm Technologies, Inc. ("iRhythm" or the "Company") (NASDAQ: IRTC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...

IRTC Investors Have Opportunity to Lead iRhythm Technologies, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, April 3, 2024 LOS ANGELES , April 3, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against iRhythm Technologies, Inc. ("iRhythm" or the "Company") (NASDAQ: IRTC ). Class Period: January 11, 2022 – May 30, 2023 Lead Plaintiff Deadline: April 8, 2024 If you...